Background: Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy. We performed a retrospective analysis of Eastern Cooperative Oncology Group (ECOG) 5592, a phase III randomized trial of platinum-based chemotherapy regimens for non-smallcell lung cancer (NSCLC), and compared outcomes in enrollees 70 years of age and older with those in younger patients. Methods: ECOG carried out a randomized phase III trial of cisplatin plus either etoposide or paclitaxel in chemotherapy-naïve NSCLC patients with stages III B or IV disease. Toxic effects, response rates, and survival rates were compared between age groups. All P values were two-sided. Results: A total of 574 patients enrolled from August 1993 through December 1994 were evaluable. Eighty-six (15%) were 70 years old or older. Older patients had a higher incidence of cardiovascular (P = .009) and respiratory (P = .04) comorbidities and nonanalgesic medication use (P = .02). Leukopenia (P<.001) and neuropsychiatric toxicity (P = .002) were more common in elderly men than in younger men. Elderly women lost more weight than younger women (P = .006). Other toxic effects were similar in older and younger patients. The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P = .66), median time to progression (4.37 versus 4.30 months; logrank test, P = .29), and survival distribution (log-rank test, P = .29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older. Baseline quality-of-life and treatmentoutcome indices were similar. Equivalent declines over time in functional well-being occurred in both groups. Conclusion: Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients, although patients
1-year survival rate, with attendant improvement in QOL (6) . Despite the obvious benefit of single-agent therapy, a bias often exists, even among those inclined to treat the elderly, against combination therapy or cisplatin-based treatment.
Although cisplatin-based therapy has yielded improved survival in patients with advanced NSCLC (3, 7) , the role of combination therapy, particularly cisplatin-based treatment, in the elderly has not been explored systematically. In retrospective multivariate and recursive partitioning analyses of the Eastern Cooperative Oncology Group (ECOG) database in which patients received multiple different regimens, most platinumbased, age did not prove to be an important factor in determining prognosis (8, 9) . To systematically examine whether advanced age compromises outcome or exacerbates toxicity, we performed a retrospective analysis of patients enrolled on ECOG 5592, a phase III study employing a fixed dose of cisplatin and randomly assigning patients to receive either standard therapy (etoposide) or two different doses of paclitaxel. This study, previously reported by Bonomi et al. (10) , demonstrated an outcome benefit for patients randomly assigned to treatment with paclitaxel and cisplatin ( Table 1 ). The effect of age on outcome or toxicity, however, was not explored explicity. Fig. 1 provides information about accrual, randomization, and availability of patients for analysis. Eligibility stipulated histologically or cytologically confirmed NSCLC; bidimensional measurable or evaluable stage III, stage IV, or recurrent disease; ECOG PS of 0 or 1; no history of malignant disease in the previous 5 years, with the exception of skin cancer or in situ carcinoma of the cervix; and no brain metastasis. In addition, enrollment mandated adequate organ function defined as follows: a leukocyte count of greater than or equal to 4000/mm 3 , a platelet count of greater than or equal to 100 000/mm 3 , a bilirubin level of less than or equal to 1.5 mg/dL, and a serum creatinine level of less than or equal to 1.5 mg/dL. A minimum age of 18 years was required. There were no upper age restrictions. Active infections rendered patients ineligible, as did prior chemotherapy or mixed small-cell and non-small-cell histology.
PATIENTS AND METHODS Eligibility
Patients were permitted prior radiation therapy, as long as it had been completed 2 weeks or more before trial entry. However, patients whose only measurable lesion was within a previous radiation portal were deemed to be ineligible. Additional exclusion criteria included uncontrolled diabetes mellitus (random blood sugar level >200 mg/dL), uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, or evidence of pre-existing peripheral neuropathy. Written informed consent, in accordance with the institutional review board of each participating institution, was required before study entry. Patients were accrued from the ECOG, a consortium of academic and community cancer centers and practices across North America and South Africa.
Randomization
Patients were given a fixed dose of cisplatin at 75 mg/m 2 and were randomly assigned to one of three distinct chemotherapy regimens as follows: 1) etoposide-cisplatin regimen (EC)-cisplatin administered over a 1-hour period on day 1 and etoposide at a dose of 100 mg/m 2 administered intravenously over a 45-minute period on days 1, 2, and 3; 2) high-dose paclitaxel regimen (PCG)-paclitaxel at a dose of 250 mg/m 2 administered intravenously by 24-hour infusion on day 1, followed by cisplatin on day 2, plus granulocyte colony-stimulating factor, at 5 g/kg subcutaneously beginning on day 3 and continuing until the granulocyte count rose above 10 000/mm 3 ; and 3) low-dose paclitaxel regimen (PC)-paclitaxel at a dose of 135 mg/m 2 given intravenously by 24-hour infusion on day 1, followed by cisplatin on day 2. In the absence of persistent toxicity or evidence of disease progression, treatment was cycled at 21-day intervals.
Stratification parameters included the following: ECOG PS of 0 versus 1 (11) , weight loss during the previous 6 months of less than 5% versus greater than or equal to 5%, stage IIII B versus stage IV disease (12) , and bidimensional measurable disease versus evaluable disease.
History and physical examination, complete blood cell count, and serum chemistries were performed before each treatment cycle. Tumor measurements were obtained after every two cycles. QOL, based on the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale (13) , was assessed at baseline and periodically over the course of treatment. Toxicity and tumor responses were defined according to ECOG criteria (14) .
Statistical Methods
The accrual goal of the study (585 patients) was estimated to yield a greater than 90% power to detect a 50% increase in median survival from 6 months on standard treatment to 9 months on either of the paclitaxel regimens, with an experimental type 1 significance level of 5%, by use of an O'BrienFleming type group sequential method (15, 16 (19) , and the log-rank test (20) was used for survival comparisons. All P values were two-sided.
For this analysis, patient characteristics were broken down by age (<70 years versus ജ70 years) and sex and included treatment assignment, race, PS, weight loss in previous 6 months, disease stage, prior therapy, primary disease symptoms, metastatic disease symptoms, presence of paraneoplastic syndrome, systemic symptoms, associated chronic diseases, chronic medications, initial laboratory values, histology, and sites of metastatic lesions. Fisher's exact test and the Kruskall-Wallis test were used to compare proportions and distributions of variables between the two groups. Fisher's exact test (17) was also used to compare response rates between the two groups, with confidence intervals (CIs) for response estimated by use of exact binomial CIs (21) . Survival curves were estimated by the method of Kaplan and Meier (19) . The method of Mehta et al. (22) was used to test for differences in patterns of toxicity between younger and older patients.
Quality of Life
QOL was assessed by version 2 of the FACT-L instrument (18) , consisting of 35 questions, each scored using a 5-point scale: 1) 0 ‫ס‬ not at all, 2) 1 ‫ס‬ a little bit, 3) 2 ‫ס‬ somewhat, 4) 3 ‫ס‬ quite a bit, and 5) 4 ‫ס‬ very much. The questions addressed six areas: 1) physical well-being, 2) functional well-being, 3) lung cancer symptoms, 4) social well-being, 5) emotional wellbeing, and 6) relationship with doctor. A subgroup of 21 questions relating to physical well-being, functional well-being, and lung cancer symptoms was combined in a designated trial outcome index (TOI), which, based on prior studies, was considered to be the best summary indicator of the physical component of QOL (13) . Patients were asked to complete the FACT-L questionnaire before the first course of chemotherapy and again 6, 12, and 26 weeks later. Numeric values for each item were added to obtain the total score and scores for subsets of questions, such as the TOI. Each patient was classified according to his/her QOL response. The QOL response category for individual patients was determined by calculating the difference between a baseline TOI score and the TOI scores at 6, 12, and 26 weeks. In addition, we compared baseline QOL between patients aged 70 years and older and patients less than 70 years of age. For patients completing the 6-month assessment, we also computed a differential score between baseline and 6-month QOL. A Student's t test was used to compare each of these QOL measures, with appropriate P values assigned. Because missing data at later time points might have been related to both QOL and survival status, the method of analysis suggested by Schluchter (23) was employed to test for age-related differences in FACT-L scores. Schluchter's method jointly models the longitudinal QOL assessments and survival to better control for possible bias because of differential missing data in the two groups. With the use of this method, missing observations that occurred after the last observed measurements were assumed to be informatively missing (i.e., not missing at random). The longitudinal model is the random-effects model proposed by Laird and Ware (24) . The survival model is a log-normal model. 
RESULTS
From August 1993 through December 1994, a total of 599 patients were enrolled in the trial; 574 were evaluable. The reasons for cancellation and ineligibility have been delineated previously (10) . Patient demographics are summarized in Table 2. A total of 488 patients were under 70 years of age; 86 (15%) were 70 years of age or older. There was equal distribution across sex, race, PS, pretreatment weight loss, disease stage (III B versus IV), and prior radiation therapy. A significant increase in comorbid conditions, including cardiovascular disease (P ‫ס‬ .009) and respiratory disease (P ‫ס‬ .04), was observed in older patients. There was no difference with respect to prior analgesic usage or need for corticosteroids, although older patients exceeded younger patients in their use of other medications (P ‫ס‬ .015).
Pretreatment symptoms and sites of disease are also summarized in Table 2 . A slightly higher proportion of younger patients experienced cough (P ‫ס‬ .10) and hoarseness (P ‫ס‬ .09). There were no statistically significant differences with respect to symptoms of respiratory infection, as well as other primary symptoms, hemoptysis, dyspnea, chest pain, Pancoast symptoms, bone pain, or appetite loss.
Older patients had a slightly higher percentage of squamous histology and a slightly lower percentage of adenocarcinoma, but this trend was statistically nonsignificant (two-sided Fisher's exact test, P ‫ס‬ .15). The elderly had a significantly lower incidence of mediastinal involvement (P ‫ס‬ .009) and a trend toward more hepatic involvement (P ‫ס‬ .07) but no other differences in sites of metastases. There was no difference in baseline levels of albumin, lactate dehydrogenase, or alkaline phosphatase using Kruskal-Wallis tests.
Treatment Distribution
Among subjects under 70 years, 35% received EC, 33% received PCG, and 32% received PC, while, among subjects 70 years old or older, 26%, 37%, and 37% received EC, PCG, and PC, respectively. No statistically significant difference in the distributions of treatment received was observed between the two groups (two-sided Fisher's exact test, P ‫ס‬ .22). Table 3 shows the clinical response rates. Of 488 patients under 70 years of age, 105 had either a complete or a partial response (22%; 95% CI ‫ס‬ 18% to 25%). Of 86 subjects 70 years old or older, 20 achieved a complete or a partial response (23%; 95% CI ‫ס‬ 15% to 34%). No statistically significant difference in response rates between the two groups was observed (P ‫ס‬ .67). Of note, a slightly higher proportion of younger patients (50.6%) had progressive disease as their best overall response compared with older patients (40.7%). When we grouped patients with stable disease with responders and compared the elderly with younger patients, there was no statistically significant difference in outcome (P ‫ס‬ .15). There were no sex-related differences in response rate. Among the elderly, 16 (25%) of 64 subjects receiving taxane-containing regimens had either a complete or a partial response (95% CI ‫ס‬ 15% to 37%), whereas four (18%) of 22 receiving EC responded (95% CI ‫ס‬ 5.2% to 40%); among subjects less than 70 years old, 85 (27%) of 317 randomly selected to receive taxane-containing regimens responded (95% CI ‫ס‬ 22% to 32%), whereas 20 (12%) of 171 patients receiving EC responded (95% CI ‫ס‬ 7.3% to 17%).
Clinical Response Rates

Survival and Time to Disease Progression
There was no statistically significant difference in the distribution of survival times between the two groups (P ‫ס‬ .29). Overall median survival time in patients younger than 70 years ‡Patients whose best response was either progressive disease or no change.
was 9.05 months compared with 8.53 months in patients 70 years old or older. At 1 year, the relative survival rates were 37.7% and 29.1%, respectively; at 2 years, they were 13.5% and 11.6%, respectively. The relative survival curves are depicted in Fig. 2 , A. Among the elderly, there was no statistically significant difference in survival times between patients receiving the taxane-containing regimen and those receiving EC (P ‫ס‬ .62).
For the elderly receiving either PC or PCG, the median survival time and the 2-year survival proportion were 9.2 months and 12%, respectively, compared with 6.34 months and 9%, respectively, for those receiving EC. There was no statistically significant difference with respect to time to progression (P ‫ס‬ .29). At 1 year, 11.3% of subjects under 70 years of age were free from progression compared with 15.1% of those 70 years of age or older. The median time to progression in each group was 4.37 and 4.30 months, respectively. Median time to progression for the elderly receiving EC was 2.76 versus 5.29 months for those receiving PC or PCG (log-rank test, P = .36). Time to progression curves are shown in Fig. 2, B .
Sex had no influence on survival or time to progression in either age cohort. The median overall survival time in the group of male subjects less than 70 years old was 8.64 months; it was 7.72 months in the group 70 years of age or older. The median time to progression was 4.14 and 3.84 months for male subjects in the less than 70-year group and greater than or equal to 70-year group, respectively. There were no statistically significant differences with respect to overall survival and time to progression between the two groups (overall survival, P ‫ס‬ .0863; time to progression, P ‫ס‬ .3864). The median overall survival time in the group of female subjects less than 70 years old was 9.79 months; it was 10.25 months in the group 70 years old or older. The median time to progression was 4.83 and 5.52 months for the female subjects in the less than 70-year group and greater than or equal to 70-year group, respectively. There were no statistically significant differences with respect to overall survival and time to progression between the two groups (overall survival, P ‫ס‬ .6540; time to progression, P ‫ס‬ .5527).
Toxicity
All patients (n ‫ס‬ 588), regardless of eligibility, were included in the toxicity analyses. Toxic effects by maximum grade are detailed separately for males and for females in Table 4 . Overall, older males were more likely to experience high-grade leukopenia (P<.001) then their younger counterparts (42% versus 17%), and they had a higher incidence of neuropsychiatric toxicity (P ‫ס‬ .002) (17% grade ജ2 versus 7%), although the precise nature of this toxicity was not delineated. In addition, the severity of toxicity or worst degree of toxicity manifest was significantly higher in elderly males (P ‫ס‬ .007). There was a 7% incidence of grade 5 toxicity in males 70 years old or older versus 3% in males under 70 years. Of seven grade 5 events occurring in the elderly, five occurred in the high-dose paclitaxel group (three in the setting of neutropenic fever). Four of the grade 5 events among the elderly occurred in males and three occurred in females. Elderly women were likely to experience more severe weight loss than younger women; 33% of elderly women had weight loss of 10% or more compared with 17% of younger women. No other differences in toxicity were observed between younger and older patients.
Quality of Life
QOL was assessed at baseline, at 6 weeks, at 3 months, and at 6 months ( Table 5 ). The mean scores for the entire FACT-L, the TOI, and the physical and functional well-being subscales, along with the number of assessments completed at each time point, are shown in Table 6 and Fig. 3 . We found no statistically significant differences in either baseline QOL (P ‫ס‬ .20) or changes in QOL over time (P ‫ס‬ .12) between younger and older males. Among female patients, older patients had higher scores at baseline on the FACT-L instrument than younger women (114.5 versus 104.1; P ‫ס‬ .003). Older women also had less change in QOL over time (P ‫ס‬ .003). A model that assumed no association between differential missing data and survival produced similar but not identical results and resulted in the same conclusions. It should be noted that substantially fewer patients were assessed at 3 and 6 months than at baseline. Those who did not undergo 6-month evaluation were presumably sicker, had progressive disease, or had died.
Patients Greater Than or Equal to 75 Years of Age
Because concerns exist that those patients over age 75 years may be different with respect to treatment tolerance and outcome from those between the ages of 70 and 75 years, we also analyzed the older group (>75 years; n ‫ס‬ 24) and compared *CTC ‫ס‬ common toxicity criteria. †P value from Fisher's exact test. ‡Worst degree or grade of toxicity observed per patient. §Five or seven patients received high-dose paclitaxel, cisplatin, and granulocyte colony-stimulating factor; linked to neutropenia fever/sepsis. their outcome with the outcome in a slightly younger cohort (70-75 years; n ‫ס‬ 62) ( Table 6 ). Except for a borderline increased incidence of leukopenia (P ‫ס‬ .06), no discernible difference was noted, although sample size in the older group was rather small. Unfortunately, broad conclusions regarding patients 80 years of age or older could not be drawn. There were only two patients 80 years old or older: One received three cycles of therapy, and one received six cycles.
DISCUSSION
Response rates and survival rates in fit elderly NSCLC patients receiving platinum-based treatment are similar to those in younger patients. With the exception of leukopenia and neuropsychiatric toxicity, there were no obvious differences in the incidence of toxicity. This observation should pose no surprise. The relative safety of cisplatin in the elderly has been reported in several studies (25) (26) (27) (28) . There was, however, a higher incidence of life-threatening grade 4 and fatal grade 5 events, particularly in the high-dose paclitaxel arm. This finding reinforces the need to carefully screen elderly patients who are put on such trials. It also raises the potential need for elderly-specific trials that address their unique physiologic needs and take into account the increased incidence and severity of their comorbidities. It should be noted that only two patients over the age of 80 years were enrolled in ECOG 5592; hence, any conclusions derived from this analysis do not apply to the oldest age group.
Some additional caveats must be applied to this secondary analysis. First, although equivalent declines in QOL over time occurred in the elderly and in younger patients, only 21.5% of those 70 years old or older completed the 6-month assessment compared with 37.2% of those less than 70 years. This difference is substantial and may indicate that the elderly were actually doing worse than the data would suggest. In retrospect, a 6-month endpoint may have been overly ambitious. Second, the higher incidence of neutropenia in the elderly underscores the observation that hematopoietic reserve declines with age and reinforces the need to consider growth factor support, particularly in diseases like breast cancer or lymphoma, where therapeutic dose intensity is crucial (29) . Moreover, given our knowledge of neurotoxicity in the elderly and the putative increased susceptibility of peripheral nerves with age to neurotoxic agents, the absence of any difference in neurotoxicity between the elderly and younger patents is curious, if not surprising. It should be noted that the case report forms used to track toxic effects were uniformly employed during the entire course of the study; hence, no unintended biases between those 70 years old or older and those less than 70 years of age existed in recording neurotoxicity. It is conceivable, however, that those with mild baseline neurotoxicity may have overlooked or failed to report subtle exacerbations of their symptoms. Finally, neuropsychiatric toxicity, which appeared worse in the elderly, was nonspecific; chart review strongly suggests that more global symptoms, including fatigue and lassitude, were included under this rubric along with more specific symptoms of depression or cognitive compromise. Consequently, the conclusion that psychologic and/or neurocognitive distress was more pronounced in the elderly may represent an overinterpretation of the data.
To date, the optimal regimen for fit, elderly patients is not certain. No elderly-specific study has yet compared platinumbased therapy with non-platinum-based combinations or single agents. The Elderly Lung Vinorelbine Italian Study (ELVIS) Trial (6) clearly established the role of systemic therapy, specifically vinorelbine, in the elderly, including patients with an ECOG PS of 2; however, a similar elderly-specific trial comparing vinorelbine-cisplatin with vinorelbine alone has not been conducted, nor has any other comparison between cisplatin-new agent combinations and new-agent monotherapy been mounted in this age group.
Gemcitabine, like vinorelbine, appears to be a reasonable choice in the treatment of elderly NSCLC patients. The impact of age on the efficacy and tolerance of gemcitabine as a single agent in the treatment of NSCLC was evaluated by Shepherd et al. (30) in a retrospective analysis of four separate phase II trials. Those patients under 65 years of age (255 patients) were compared with those 65 years of age or older (105 patients). Response rates were 16% and 24%, respectively; median and 1-year survival rates were 8.1 months and 27% and 9.1 months and 46%, respectively. There was no overt difference in hematologic and nonhematologic toxicity, nor was there any difference in weight reduction or dose omission. Similar findings were found by Russo and Martin (31) .
Only two trials to date have compared combination chemotherapy with monotherapy in this age group. Frasci et al. (32) tested gemcitabine and vinorelbine in combination (GV) versus single-agent vinorelbine in patients 70 years old or older. The response rate for GV was 22% compared with 15% for vinorelbine. The respective median and 1-year survival rates were 29 weeks and 30% for GV versus 18 weeks and 13% for vinorelbine. The relative risk of death at multivariate analysis for GV was 0.48 (95% CI ‫ס‬ 0.29 to 0.79; P<.01). The magnitude of the survival difference and the unexpectedly poor survival results observed in the single-agent vinorelbine arm led to early termination of the study. A much larger and potentially more credible trial by the same group that mounted the ELVIS study (33) demonstrated no benefit for GV versus the single-agent constituents. The relative response rates for vinorelbine, gemcitabine, and GV were 18.5%, 17.5%, and 20%, respectively; the relative median survivals were 8.8, 6.6, and 7.6 months, respectively.
A review by investigators from Fox Chase Cancer Center (Philadelphia, PA) evaluating combination paclitaxel (by 24-or 1-hour infusion) and carboplatin demonstrated no difference in toxicity, response, or survival for older patients compared with younger patients, although a trend toward more fatigue was noted in the elderly (34) .
Our concern regarding elderly patients with NSCLC is not trivial. The incidence of lung cancer rises with advancing age; it is highest in the 70-to 80-year-old group and does not start to trail off until age 80 years or older (35) . Unfortunately, elderly patients are underrepresented in clinical trials, making it difficult to evaluate properly the efficacy and safety of current treatment options in this patient population. Data from ECOG 5592 demonstrate clearly that the elderly do as well (or as poorly) as younger patients and that any decision to deny fit elderly patients access to protocol therapy is economic, not medical. Ultimately, functional status trumps age (36).
